Porvair’s membrane filters ensure higher flow rates
Designed to withstand pressure during filtration
The rigorous construction of these pleated membrane cartridges ensures higher flow rates, lower pressure differentials and faster process times, the company says. Independently verified to meet USP Class VI and ISO 10993, each filter is provided with a certificate of quality. Manufacturing takes place in an ISO Class 5 cleanroom in accordance with accredited quality procedures and the membrane is protected from damage during production by the inner and outer drainage layers that maintain the pleat pack structure.
The filter's inner core comprises a thermoplastic material that further supports the pleat pack and draws the filtrate through its perforations to the outlet of the cartridge. Snugly encased in a polymeric outer cage and securely fitted with sanitary design adaptors that provide optimal sealing and safety against bypass, each cartridge is identified by a serial number embossed on the outer sleeve, providing full traceability to all FDA CFR 21 and EC-approved manufacturing components.
The supply chain is closely monitored with in-house production of the filter’s outer cage, core and end cap. Careful attention to package design minimises the chance of damage to the filters during transit and storage, says Porvair.
Assurance of the high quality of Porvair membrane cartridge filters is further demonstrated by post-manufacture integrity testing, which is a non-destructive means of determining oversized pores or defects.
The integrity test parameters employed by Porvair are correlated to the filter's microbial retention capabilities as determined during validation in accordance with ASTM F838-05, HIMA and PDA Technical Reports 26 and 40. Any filter that fails integrity testing is immediately discarded.
Porvair Filtration Group is an international leader in the development and supply of materials and products for applications in filtration and separation. It has offices and manufacturing sites in the UK, Europe and the US and a worldwide network of distributors.
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
Read moreThe new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?
The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?